Schering-Plough's Intron A
Executive Summary
Firm announced that its alpha-2 interferon has been approved in Canada for the treatment of hairy cell leukemia. The product is currently marketed for hairy cell leukemia in several countries including the U.K., Ireland, Columbia, the Philippines, Belgium, and Luxembourg. NDAs are pending in the U.S. for hairy cell leukemia, multiple myeloma, Kaposi's sarcoma, malignant melanoma, and prophylaxis of the common cold.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.